Old chemo drug shows promise for genetic subtype of prostate cancer

NCT ID NCT03652493

Completed Disease control Sponsor: Centre Francois Baclesse Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested the chemotherapy drug carboplatin in 16 men with metastatic castration-resistant prostate cancer that has specific gene changes in the homologous recombination pathway. The goal was to see if carboplatin could shrink tumors or lower PSA levels. The study is completed, and results may help identify which patients could benefit from this treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboplatin
What this could lead to: If successful, this could point toward a treatment option for men with a specific genetic type of advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is a small, early-phase trial with only 16 participants, so results may not apply to everyone. Carboplatin can cause side effects like low blood counts and fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic neoplasm metastatic prostate carcinoma Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION-RESISTANT PROSTATE CANCER METASTASIS

Contacts and locations

Locations

Centre François Baclesse

Caen, 14076, France
Centre Oscar Lambret

Lille, 59000, France
Chu Rouen

Rouen, 76000, France
Institut Gustave ROUSSy IGR

Villejuif, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.